Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Cheng Y, Ma L, Liu Y, Zhu J, Xin Y, Liu X, Wang Y, Zhang T, Yang C, Wang S, Cui H, Zhang L, Dai J, Shao L, Lin J, Ye J, Liu H.
Cheng Y, et al. Among authors: zhang l, zhang t.
Lung Cancer. 2020 Jul;145:63-70. doi: 10.1016/j.lungcan.2020.04.004. Epub 2020 Apr 17.
Lung Cancer. 2020.
PMID: 32408134